LivaNova (LIVN) Gross Margin (2014 - 2026)

LivaNova (LIVN) posted Gross Margin of 67.29% for Q1 2026, up 1.28% sequentially from 66.43% in Q4 2025, and down 96.0% YoY from 1682.15% in Q1 2025.

LivaNova (LIVN) Gross Margin (2014 - 2026) Analysis & Trends

LivaNova has reported Gross Margin for 13 years, with the latest figure at 67.29% in Q1 2026.

Quarterly Gross Margin fell 96.0% year-over-year to 67.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 67.48% (down 46.0% YoY) and the FY2025 annual result came in at 67.71%, down 38.0% from the prior year.
Gross Margin rose to 67.29% in Q1 2026 per LIVN's latest filing, from 66.43% in the prior quarter.
Over five years, Gross Margin peaked at 72.54% in Q2 2022 and troughed at 56.34% in Q4 2023.
A 5-year average of 67.68% and a median of 67.79% in 2025 frame the typical range for Gross Margin.
The sharpest annual moves came in 2023 and 2024: Gross Margin sank 1042 bps in 2023, then surged 1027 bps in 2024.
Over 5 years, Gross Margin stood at 66.76% in 2022, then retreated by 16 bps to 56.34% in 2023, then gained by 18 bps to 66.61% in 2024, then decreased by 0 bps to 66.43% in 2025, then climbed by 1 bps to 67.29% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 67.29%, 66.43%, and 68.44% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Abbott Laboratories	199.63 Bn	194.02 Bn	7.27 Bn	57.71%
2	Stryker	127.42 Bn	123.95 Bn	4.50 Bn	68.27%
3	Medtronic	118.97 Bn	109.75 Bn	6.41 Bn	65.35%
4	Boston Scientific	73.39 Bn	72.85 Bn	3.85 Bn	70.71%
5	Edwards Lifesciences	51.97 Bn	47.72 Bn	1.35 Bn	77.46%
6	Dexcom	34.32 Bn	32.37 Bn	830.00 Mn	63.44%
7	GE HealthCare Technologies	33.76 Bn	31.65 Bn	2.18 Bn	41.17%
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn	47.38%
9	Steris	23.04 Bn	22.56 Bn	684.20 Mn	45.84%
10	LivaNova	4.31 Bn	3.79 Bn	273.67 Mn	70.07%

Download Data